Ropes & Gray Advises AvenCell Therapeutics in $112 Million Series B Funding
October 24, 2024
October 24, 2024
BOSTON, Massachusetts, Oct. 24 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented AvenCell Therapeutics in its $112 million Series B funding round led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads VenturesJapan, Piper Heartland Healthcare Capital and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences.
AvenCell is a leading clinical-stage cell t . . .
Ropes & Gray represented AvenCell Therapeutics in its $112 million Series B funding round led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads VenturesJapan, Piper Heartland Healthcare Capital and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences.
AvenCell is a leading clinical-stage cell t . . .